{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:46:11Z","timestamp":1790721971204,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Epstein-Barr virus (EBV) is detected in some Hodgkin lymphoma (HL) tumor cells. Primary infection is associated with infectious mononucleosis and EBV+ HL. Vaccines and antiviral drugs show promise in modulating the clinical course of infectious mononucleosis. Their impact on HL is entirely unknown. T-cell function may be important in the pathogenesis of HL. In HIV patients, higher CD4 counts are associated with an increased incidence of EBV+ HL. One of the roles of the virus in the pathogenesis of HL may be to mimic signals associated with surface immunoglobulin molecules. New approaches to imaging EBV-associated tumors may be on the horizon. Adoptive immunotherapy and virus-specific pharmacologic therapies offer promise for future treatment.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.204","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Epstein-Barr Virus and Hodgkin Lymphoma"],"prefix":"10.1182","volume":"2007","author":[{"given":"Richard F.","family":"Ambinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111703034350200_R1","doi-asserted-by":"crossref","unstructured":"Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117:259\u2013267.","DOI":"10.1309\/MMAU-0QYH-7BHA-W8C2"},{"key":"2019111703034350200_R2","doi-asserted-by":"crossref","unstructured":"Glaser SL, Gulley ML, Borowitz MJ, et al. Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma. 2004;45:489\u2013497.","DOI":"10.1080\/1042819032000141310"},{"key":"2019111703034350200_R3","doi-asserted-by":"crossref","unstructured":"Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375\u2013382.","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T"},{"key":"2019111703034350200_R4","doi-asserted-by":"crossref","unstructured":"Wilson KS, Freeland JM, Gallagher A, et al. Measles virus and classical Hodgkin lymphoma: no evidence for a direct association. Int J Cancer. 2007;121:442\u2013447.","DOI":"10.1002\/ijc.22629"},{"key":"2019111703034350200_R5","doi-asserted-by":"crossref","unstructured":"Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43:276\u2013282.","DOI":"10.1086\/505400"},{"key":"2019111703034350200_R6","doi-asserted-by":"crossref","unstructured":"Tierney RJ, Edwards RH, Sitki-Green D, et al. Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis. 2006;193:287\u2013297.","DOI":"10.1086\/498913"},{"key":"2019111703034350200_R7","doi-asserted-by":"crossref","unstructured":"Balfour HH Jr, Holman CJ, Hokanson KM, et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005;192:1505\u20131512.","DOI":"10.1086\/491740"},{"key":"2019111703034350200_R8","doi-asserted-by":"crossref","unstructured":"Ambinder RF, Lin L. Mononucleosis in the laboratory. J Infect Dis. 2005;192:1503\u20131504.","DOI":"10.1086\/491746"},{"key":"2019111703034350200_R9","doi-asserted-by":"crossref","unstructured":"Woodberry T, Suscovich TJ, Henry LM, et al. Differential targeting and shifts in the immunodominance of Epstein-Barr virus\u2014specific CD8 and CD4 T cell responses during acute and persistent infection. J Infect Dis. 2005;192:1513\u20131524.","DOI":"10.1086\/491741"},{"key":"2019111703034350200_R10","doi-asserted-by":"crossref","unstructured":"Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195:893\u2013905.","DOI":"10.1084\/jem.20011692"},{"key":"2019111703034350200_R11","doi-asserted-by":"crossref","unstructured":"Williams H, McAulay K, Macsween KF, et al. The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol. 2005;129:266\u2013274.","DOI":"10.1111\/j.1365-2141.2005.05452.x"},{"key":"2019111703034350200_R12","doi-asserted-by":"crossref","unstructured":"Sauce D, Larsen M, Leese AM, et al. IL-7R alpha versus CCR7 and CD45 as markers of virus-specific CD8+ T cell differentiation: contrasting pictures in blood and tonsillar lymphoid tissue. J Infect Dis. 2007;195:268\u2013278.","DOI":"10.1086\/510248"},{"key":"2019111703034350200_R13","doi-asserted-by":"crossref","unstructured":"Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin\u2019s disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer. 2003;107:298\u2013302.","DOI":"10.1002\/ijc.11156"},{"key":"2019111703034350200_R14","doi-asserted-by":"crossref","unstructured":"Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis. N Engl J Med. 2003;349:1324\u20131332.","DOI":"10.1056\/NEJMoa023141"},{"key":"2019111703034350200_R15","doi-asserted-by":"crossref","unstructured":"Glaser SL, Keegan TH, Clarke CA, et al. Exposure to childhood infections and risk of Epstein-Barr virus\u2014defined Hodgkin\u2019s lymphoma in women. Int J Cancer. 2005;115:599\u2013605.","DOI":"10.1002\/ijc.20787"},{"key":"2019111703034350200_R16","doi-asserted-by":"crossref","unstructured":"Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 2007;67:2382\u20132388.","DOI":"10.1158\/0008-5472.CAN-06-3566"},{"key":"2019111703034350200_R17","doi-asserted-by":"crossref","unstructured":"Moutschen M, Leonard P, Sokal EM, et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine. 2007;25:4697\u20134705.","DOI":"10.1016\/j.vaccine.2007.04.008"},{"key":"2019111703034350200_R18","doi-asserted-by":"crossref","unstructured":"Balfour HH Jr, Hokanson KM, Schacherer RM, et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol. 2007;39:16\u201321.","DOI":"10.1016\/j.jcv.2007.02.002"},{"key":"2019111703034350200_R19","doi-asserted-by":"crossref","unstructured":"Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467\u20131473.","DOI":"10.1158\/1078-0432.CCR-04-1869"},{"key":"2019111703034350200_R20","doi-asserted-by":"crossref","unstructured":"Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108:2280\u20132289.","DOI":"10.1182\/blood-2006-04-015164"},{"key":"2019111703034350200_R21","doi-asserted-by":"crossref","unstructured":"Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988\u20131998. Cancer. 2003;98:300\u2013309.","DOI":"10.1002\/cncr.11459"},{"key":"2019111703034350200_R22","doi-asserted-by":"crossref","unstructured":"Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS. Blood. 2006;108:3786\u20133791.","DOI":"10.1182\/blood-2006-05-024109"},{"key":"2019111703034350200_R23","doi-asserted-by":"crossref","unstructured":"O\u2019Grady J, Stewart S, Elton RA, Krajewski AS. Epstein-Barr virus in Hodgkin\u2019s disease and site of origin of tumour. Lancet. 1994;343:265\u2013266.","DOI":"10.1016\/S0140-6736(94)91114-2"},{"key":"2019111703034350200_R24","doi-asserted-by":"crossref","unstructured":"Aozasa K, Takakuwa T, Nakatsuka S. Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation. Adv Anat Pathol. 2005;12:324\u2013331.","DOI":"10.1097\/01.pap.0000194627.50878.02"},{"key":"2019111703034350200_R25","doi-asserted-by":"crossref","unstructured":"Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin\u2019s and Reed\/Sternberg cells in Hodgkin\u2019s lymphoma. Int J Cancer. 2006;118:1853\u20131861.","DOI":"10.1002\/ijc.21716"},{"key":"2019111703034350200_R26","doi-asserted-by":"crossref","unstructured":"Portis T, Dyck P, Longnecker R. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;102:4166\u20134178.","DOI":"10.1182\/blood-2003-04-1018"},{"key":"2019111703034350200_R27","doi-asserted-by":"crossref","unstructured":"Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of \u201ccrippled\u201d germinal center B cells from apoptosis by Epstein-Barr virus. Blood. 2005;106:4339\u20134344.","DOI":"10.1182\/blood-2005-06-2341"},{"key":"2019111703034350200_R28","doi-asserted-by":"crossref","unstructured":"Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood. 2005;106:4345\u20134350.","DOI":"10.1182\/blood-2005-06-2342"},{"key":"2019111703034350200_R29","doi-asserted-by":"crossref","unstructured":"Chaganti S, Bell AI, Pastor NB, et al. Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood. 2005;106:4249\u20134252.","DOI":"10.1182\/blood-2005-06-2327"},{"key":"2019111703034350200_R30","doi-asserted-by":"crossref","unstructured":"Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin\u2019s lymphoma: a population-based study. J Clin Oncol. 2005;23:7604\u20137613.","DOI":"10.1200\/JCO.2005.02.6310"},{"key":"2019111703034350200_R31","doi-asserted-by":"crossref","unstructured":"Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin\u2019s lymphoma. Ann Hematol. 2006;85:463\u2013468.","DOI":"10.1007\/s00277-006-0081-9"},{"key":"2019111703034350200_R32","doi-asserted-by":"crossref","unstructured":"Herling M, Rassidakis GZ, Vassilakopoulos TP, Medeiros LJ, Sarris AH. Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. Blood. 2006;107:1240; author reply 1241.","DOI":"10.1182\/blood.V107.3.1240.1240"},{"key":"2019111703034350200_R33","doi-asserted-by":"crossref","unstructured":"Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979\u20133981.","DOI":"10.1182\/blood-2003-12-4287"},{"key":"2019111703034350200_R34","doi-asserted-by":"crossref","unstructured":"Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414\u20135418.","DOI":"10.1200\/JCO.2006.07.7982"},{"key":"2019111703034350200_R35","doi-asserted-by":"crossref","unstructured":"Fan H, Gulley ML. Epstein-Barr viral load measurement as a marker of EBV-related disease. Mol Diagn. 2001;6:279\u2013289.","DOI":"10.2165\/00066982-200106040-00009"},{"key":"2019111703034350200_R36","doi-asserted-by":"crossref","unstructured":"Fu DX, Tanhehco YC, Chen J, et al. Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res. 2007;13:1453\u20131458.","DOI":"10.1158\/1078-0432.CCR-06-2295"},{"key":"2019111703034350200_R37","doi-asserted-by":"crossref","unstructured":"Savoldo B, Rooney CM, Di Stasi A, et al. Epstein barr virus\u2013specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin\u2019s disease. Blood. 2007;110:2620\u20132630.","DOI":"10.1182\/blood-2006-11-059139"},{"key":"2019111703034350200_R38","doi-asserted-by":"crossref","unstructured":"Bollard CM, Gottschalk S, Huls MH, et al. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47:837\u2013842.","DOI":"10.1080\/10428190600604724"},{"key":"2019111703034350200_R39","doi-asserted-by":"crossref","unstructured":"Bollard CM, Huls MH, Buza E, et al. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006;6:342\u2013347.","DOI":"10.3816\/CLM.2006.n.011"},{"key":"2019111703034350200_R40","doi-asserted-by":"crossref","unstructured":"Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease. J Exp Med. 2004;200:1623\u20131633.","DOI":"10.1084\/jem.20040890"},{"key":"2019111703034350200_R41","doi-asserted-by":"crossref","unstructured":"Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother. 2001;45:2082\u20132091.","DOI":"10.1128\/AAC.45.7.2082-2091.2001"},{"key":"2019111703034350200_R42","doi-asserted-by":"crossref","unstructured":"Perrine SP, Hermine O, Small T, et al. A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109:2571\u20132578.","DOI":"10.1182\/blood-2006-01-024703"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/204\/646150\/204_209ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/204\/646150\/204_209ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:04:01Z","timestamp":1573977841000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/204\/19162\/EpsteinBarr-Virus-and-Hodgkin-Lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.204","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}